Lurasidone-Induced Tardive Syndrome.

Area of Science:

• Neuroscience
• Psychopharmacology

Background:

• Tardive syndrome (TS) is an irreversible movement disorder linked to dopamine receptor-blocking agents (DRBAs).
• While typical antipsychotics are known causes, atypical antipsychotics also pose a risk for TS.

Observation:

• This case series details four patients who developed movement disorders after using lurasidone, an atypical antipsychotic approved in 2013.
• The observed conditions included tardive dystonia, tardive akathisia, and drug-induced parkinsonism.
• Lurasidone was prescribed for bipolar disorder and schizophrenia in these patients.

Findings:

• Lurasidone, a newer atypical antipsychotic, has been associated with the development of tardive syndrome (TS) and parkinsonism.
• The study highlights that movement disorders are considered rare side effects of lurasidone, potentially leading to underestimation of the risk.
• The cases suggest that lurasidone can cause disabling and irreversible TS.

Implications:

• Healthcare providers may have a false sense of security regarding lurasidone's side effect profile for movement disorders.
• Increased awareness and caution are necessary when prescribing lurasidone due to its potential to cause irreversible TS and parkinsonism.
• Further research into the long-term effects and risk factors for TS with atypical antipsychotics like lurasidone is warranted.